Daily Ards Research Analysis
Analyzed 14 papers and selected 3 impactful papers.
Summary
Three ARDS-focused studies stood out: an open-source EHR classifier reliably identified patients with persistent moderate–severe ARDS across multicenter cohorts; a prospective ECMO study uncovered a high burden of post-decannulation sepsis and the added diagnostic yield of microbial cfDNA sequencing; and a Mendelian randomization analysis challenged simple causal links between gut microbiota/immune factors and ARDS. Together, they advance phenotyping, infection surveillance, and causal inference in ARDS.
Research Themes
- EHR-based phenotyping and enrichment of persistent moderate–severe ARDS
- Post-ECMO decannulation sepsis and advanced pathogen diagnostics (cfDNA NGS)
- Genetically informed causal inference of microbiome–immune axes in ARDS
Selected Articles
1. An Electronic Health Record-Based Classifier for Moderate-to-Severe Acute Respiratory Distress Syndrome With Persistent Hypoxemia.
Across multicenter development (N=924) and validation (N=90) cohorts, an open-source EHR classifier requiring persistent PaO2/FiO2 ≤150 or severe hypoxemia-directed interventions within 24 h achieved PPVs of 71% and 66% for clinician-adjudicated ARDS. Using SpO2/FiO2 ≤162 expanded case capture but lowered PPV (67% and 62%).
Impact: It operationalizes a reproducible, scalable ARDS phenotype using routine data, enabling trial enrichment and quality improvement targeting patients with persistent moderate–severe hypoxemia.
Clinical Implications: Supports near-real-time or retrospective screening for persistent moderate–severe ARDS to trigger evidence-based interventions (e.g., prone positioning, neuromuscular blockade) and to enrich clinical trials.
Key Findings
- Primary EHR classifier identified 382/924 development and 38/90 validation patients with persistent moderate–severe ARDS.
- Positive predictive value was 71% (95% CI 66–75%) in development and 66% (95% CI 50–81%) in validation cohorts.
- Using SpO2/FiO2 ≤162 increased case yield but reduced PPV to 67% (development) and 62% (validation).
Methodological Strengths
- Multicenter cohorts with temporal and geographic external validation against clinician-adjudicated ARDS
- Pre-specified, objective EHR criteria and open-source implementation enabling reproducibility
Limitations
- Retrospective design with performance primarily reported as PPV; sensitivity/specificity and impact on outcomes were not detailed in the abstract
- Generalizability may vary with local documentation practices and gas exchange measurement availability
Future Directions: Prospective, real-time deployment with alerting to test sensitivity/specificity and evaluate whether classifier-guided care improves outcomes; assess transportability across health systems.
OBJECTIVES: To characterize the performance of an electronic health record (EHR) data-based classifier of persistent moderate-to-severe acute respiratory distress syndrome (ARDS). DESIGN: Retrospective observational study. SETTING: Six ICUs from two health systems. PATIENTS: We included adults receiving greater than or equal to 24 hours of invasive mechanical ventilation (IMV) with a Pao2/Fio2 of less than or equal to 150 mm Hg on Fio2 greater than or equal to 0.6 in the first 72 hours of IMV. We evaluated classifier performance in two temporally and geographically distinct cohorts: a development cohort including patients in one of two academic medical or three mixed community ICUs in the first 3 months of 2021 or in 2022-2023, and a validation cohort from a different academic medical ICU in 2017. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: In both cohorts, study physicians assessed patients for clinical ARDS criteria. We retrospectively applied the EHR classifier, which required a persistent Pao2/Fio2 of less than or equal to 150 mm Hg or receipt of interventions to address severe hypoxemia (i.e., prone positioning, neuromuscular blockade, inhaled pulmonary vasodilators) in the 24 hours after initially meeting hypoxemia criteria. We also evaluated classifier definitions that used peripheral oxygen saturation (Spo2)/Fio2 of less than or equal to 162 to indicate persistent hypoxemia. Of 924 patients in the development cohort, 504 (55%) had clinician-adjudicated ARDS. Of 90 patients in the validation cohort, 48 (53%) had clinician-adjudicated ARDS. In the development and validation cohorts, the primary EHR-based classifier identified 382 and 38 patients as having persistent moderate-to-severe ARDS, respectively (positive predictive value [PPV], 71%; 95% CI, 66-75% and PPV, 66%; 95% CI, 50-81%). When Spo2/Fio2 was used as the second hypoxemia marker more patients were classified as ARDS in both development and validation cohorts but with lower PPVs (67% and 62%, respectively.). CONCLUSIONS: An EHR-based classifier using readily available data had acceptable performance for identifying patients with persistent moderate-severe ARDS. This open-source tool could be used for retrospective or prospective identification of this vulnerable population for research and quality improvement initiatives.
2. Prevalence and microbiological profile of septic complications following ECMO decannulation: a prospective single-center study.
In 18 ECMO patients (mostly VV-ECMO), post-decannulation sepsis occurred in 56%, with 33% having positive blood cultures within 10 minutes of decannulation. Microbial cfDNA NGS identified pathogens in 75% and revealed additional organisms in 42%, implicating biofilm-related pathogens and supporting integrated surveillance.
Impact: It prospectively quantifies a high sepsis burden at ECMO decannulation and demonstrates added diagnostic yield from cfDNA NGS beyond standard cultures.
Clinical Implications: Consider protocolized sampling (immediate post-decannulation blood cultures) and integrated microbiological surveillance including cfDNA NGS to detect early pathogens and guide antimicrobial strategies.
Key Findings
- Post-decannulation sepsis occurred in 10/18 patients (56%; 95% CI 31–79%).
- Blood cultures taken within 10 minutes of decannulation were positive in 6/18 (33%).
- cfDNA NGS identified pathogens in 9/12 (75%) and found additional organisms beyond standard diagnostics in 5/12 (42%); viral pathogens in 3/12 (25%).
- Pre-ECMO ventilation duration correlated negatively with biofilm-forming bacteria in blood during ECMO (r = −0.7, p = 0.002).
Methodological Strengths
- Prospective cohort with predefined peri-decannulation sampling and Sepsis-3 definitions
- Use of biofilm assessment and microbial cfDNA NGS alongside standard cultures; registered protocol
Limitations
- Small, single-center sample limits generalizability and statistical power
- Observational design precludes causal inference; NGS findings require clinical correlation and may be affected by contamination or interpretation challenges
Future Directions: Larger multicenter cohorts to validate incidence and timing, evaluate preventive strategies at decannulation, and define the clinical utility and stewardship impact of cfDNA NGS-guided management.
Extracorporeal membrane oxygenation (ECMO) is widely used to manage acute respiratory distress syndrome (ARDS); however, biofilm formation on cannulas may contribute to infections. This study investigated the prevalence, timing, and microbial profiles of infectious complications following ECMO decannulation. This prospective, single-center cohort study was conducted in the mixed medical-surgical intensive care unit (ICU) at the University Hospital Essen (01/2022-01/2023). Adults who received ECMO for > 48 h were included. Microbiological sampling (blood cultures and wound swabs) was performed before and after decannulation. Cannulas were assessed for biofilms, and plasma samples were analyzed using next-generation sequencing (NGS) of microbial cell-free DNA (cfDNA). Sepsis was defined according to the most recent Sepsis-3 criteria. The study included 18 patients (56% men); 17 received VV-ECMO and one received VA-ECMO. Post-decannulation sepsis occurred in 10 of 18 patients (56%; 95% CI: 31-79%), and overall infectious complications were observed in 72% of patients. A strong negative correlation was evident between pre-ECMO ventilation duration and biofilm-forming bacteria in the blood during ECMO (r = - 0.7, p = 0.002). Blood cultures obtained within 10 min of decannulation were positive in 6 of 18 (33%) patients. NGS identified pathogens in 9 of 12 patients (75%), with 5 (42%) revealing additional organisms not detected by conventional methods. Viral pathogens were detected in 3 of 12 (25%) patients using NGS. Patients with sepsis demonstrated higher antibiotic consumption (p = 0.012) and more frequently met SOFA-based sepsis criteria (p = 0.007), whereas other parameters were comparable. Sepsis and infection frequently occur after ECMO decannulation and may be associated with biofilm-related pathogens. NGS has improved pathogen detection beyond standard diagnostics, although the findings require clinical correlation. These prospective findings support the need for further investigation of advanced integrated microbiological surveillance post-ECMO in larger multicenter studies.Trial registration: DRKS, DRKS00024842. Registered 12 Apr 2021, https://drks.de/search/de/trial/DRKS00024842.
3. Casual roles of gut microbiota, immune cells, and inflammatory cytokines in acute respiratory distress syndrome: A Mendelian randomization study.
Two-sample MR using multiple robustness checks found no FDR-significant overall causal effects of gut taxa, immune-cell phenotypes, or cytokines on ARDS, although nominal associations (P<.05) were observed for 12 taxa, 24 immune cells, and 6 cytokines. Mediation by EIF4EBP1, caspase-8, IL-6, and IL-8 was not supported after BCa bootstrap.
Impact: By leveraging genetic instruments, this study refines the causal landscape of microbiome–immune pathways in ARDS and tempers premature translational claims, guiding more precise mechanistic targeting.
Clinical Implications: Discourages immediate clinical adoption of microbiome/immune modulation for ARDS based solely on associative studies; supports prioritizing targets with stronger causal evidence in future trials.
Key Findings
- After FDR adjustment, overall causal effects of gut taxa, immune cells, and cytokines on ARDS were not statistically significant (PFDR < 0.2).
- Nominal associations (P < .05) were observed for 12 gut microbiota taxa, 24 immune-cell phenotypes, and 6 circulating cytokines.
- Mediation analyses initially implicating EIF4EBP1, caspase-8, IL-6, and IL-8 were rejected after 1000 BCa bootstrap iterations.
Methodological Strengths
- Two-sample MR with IVW primary estimates and multiple sensitivity analyses (Cochran’s Q, MR-Egger, leave-one-out, reverse MR)
- FDR correction and bootstrap mediation analyses to probe indirect pathways
Limitations
- Reliance on summary-level instruments may reduce power and introduce weak instrument bias; ARDS phenotype heterogeneity across datasets
- Most associations did not survive FDR correction; mediation pathways were not supported after bootstrap
Future Directions: Larger ARDS GWAS with harmonized phenotyping, multi-ancestry instruments, and integrative multi-omics (metagenomics, proteomics) MR to pinpoint robust causal targets.
Gut dysbiosis and aberrant immune activation are increasingly recognized as critical determinants of acute respiratory distress syndrome (ARDS). However, the causal contributions of specific gut taxa, immune-cell phenotypes, and their interactive pathways remain incompletely understood. In this study, we conducted a comprehensive two-sample Mendelian randomization (MR) analysis to elucidate the individual and combined effects of the gut microbiome and immune milieu on ARDS susceptibility. Using 5 combined methodologies, the primary causal estimates were primarily derived through the Inverse-Variance Weighted approach. Heterogeneity was evaluated using Cochrane's Q test, while horizontal pleiotropy was assessed via the MR-Egger intercept, and robustness was confirmed through leave-one-out and reverse MR analyses. Following adjustments for the false discovery rate (FDR), our findings indicated that, although the overall effects of exposures on ARDS were not statistically significant (PFDR < 0.2), there were causal associations identified for 12 gut microbiota taxa, 24 immune cells, and 6 circulating inflammatory cytokines with ARDS (P < .05). Initial mediation analyses indicated that EIF4EBP1, caspase-8, IL-6, and IL-8 might partly mediate these effects, but 1000 BCa bootstrap iterations rejected all indirect pathways. These findings underscore the pivotal roles of gut microbiota and immune factors, both individually and interactively, in the pathogenesis of ARDS, offering a genetically informed basis for future treatments targeting the microbiome and immune system.